NEW HAVEN, Conn., July 20, 2026
Biohaven Ltd. has announced that new Phase I clinical data for BHV-1530, its investigational FGFR3-directed antibody-drug conjugate (ADC) featuring a proprietary Topoisomerase I (TopoIx) payload, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. Alongside the scientific presentation, the company also revealed a new clinical supply agreement with Regeneron Pharmaceuticals to evaluate BHV-1530 in combination with cemiplimab (Libtayo®), an anti-PD-1 immune checkpoint inhibitor. The announcement highlights Biohaven’s continued advancement in precision oncology, with early clinical findings demonstrating encouraging anti-tumor activity, a differentiated safety profile, and the potential to significantly expand treatment options for patients with FGFR3-positive and FGFR3 wild-type overexpressing solid tumors.
Phase I Results Demonstrate Early Clinical Activity Across Multiple Tumor Types
The updated Phase I dose-escalation study has shown encouraging evidence of anti-tumor activity in patients with advanced solid tumors harboring both FGFR3 genetic alterations and wild-type FGFR3 overexpression. Among the most notable findings was a heavily pretreated patient with metastatic urothelial cancer carrying an FGFR3-TACC3 fusion, who experienced tumor reduction after progressing through multiple previous therapies, including Padcev®, pembrolizumab, and two FGFR-targeted tyrosine kinase inhibitors. Importantly, investigators reported no FGFR-related toxicities in this patient. Across the ongoing study, BHV-1530 has demonstrated no dose-limiting toxicities and has avoided the common adverse events associated with currently approved FGFR inhibitors, including hyperphosphatemia, nail disorders, stomatitis, and retinopathy. These findings suggest the investigational ADC may offer a broader therapeutic window while maintaining favorable tolerability in patients with difficult-to-treat cancers.
Novel ADC Expands Treatment Potential Beyond Traditional FGFR Inhibitors
Unlike conventional FGFR tyrosine kinase inhibitors (TKIs), which are primarily limited to patients carrying FGFR3 genomic alterations, BHV-1530 is specifically designed to target FGFR3 protein expression regardless of mutation status. This unique mechanism could substantially increase the eligible patient population, particularly in metastatic urothelial carcinoma, where approximately 50% of tumors overexpress FGFR3, despite only 15–20% carrying FGFR3 mutations. The investigational therapy combines a highly selective FGFR3-targeting antibody with Biohaven’s proprietary TopoIx payload, enabling targeted delivery of chemotherapy directly to tumor cells while minimizing systemic toxicity. The ongoing Phase I clinical trial is enrolling patients with advanced urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and additional FGFR3-expressing solid tumors that have progressed following standard-of-care therapies.
Advertisement
Biohaven and Regeneron Expand Immuno-Oncology Collaboration
To further strengthen the clinical development program, Biohaven has entered into a new clinical supply agreement with Regeneron Pharmaceuticals to evaluate BHV-1530 in combination with cemiplimab (Libtayo®). Preclinical studies have demonstrated that the ADC’s proprietary TopoIx payload induces immunogenic cell death, stimulating anti-tumor immune responses and creating a compelling scientific rationale for combination with PD-1 checkpoint inhibition. The agreement expands the existing collaboration between the two companies, which already includes Biohaven’s BHV-1510 TROP2-directed ADC program. Combination cohorts evaluating BHV-1530 with anti-PD-1 therapy are expected to begin during the second half of 2026, reflecting Biohaven’s broader strategy of developing innovative antibody-drug conjugates capable of improving outcomes across multiple solid tumor indications. The upcoming ESMO 2026 presentation is expected to provide further insight into the clinical potential of this first-in-class precision oncology therapy.
Source: Biohaven press release
